Public company intelligence preview
GRI BIO INC
18 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $540420.37 average total compensation across covered insiders.
Governance movement
Public aggregate: 1 governance events in the last year.
Institutional ownership
Public aggregate: 7 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
GRI BIO INC is a Healthcare sector, Biotechnology company focused on developing therapies for serious inflammatory, fibrotic, and autoimmune diseases. Its lead asset, GRI-0621, is being advanced for idiopathic pulmonary fibrosis, a high-unmet-need, progressive lung disease, while GRI-0803 is being developed for systemic lupus erythematosus and lupus nephritis. The company is still clinical-stage and has no product revenue, so its value is primarily tied to clinical results, regulatory milestones, and financing success. Its small operating footprint, reliance on contract manufacturers, and limited internal staff make execution highly dependent on external partners and capital availability.
Executive Compensation Practices
In a company like GRI BIO, executive compensation is typically structured to preserve cash while rewarding clinical and financing milestones. Because the business is still pre-commercial and heavily R&D-driven, pay packages often rely on stock options, restricted stock, and milestone-based bonuses rather than large cash salaries alone. The filing summaries suggest compensation pressure may be tied to advancing GRI-0621 through FDA discussions, a planned Phase 2b study, and progress on GRI-0803, since those are the main value-creation events. The reported rise in stock-based compensation and personnel costs also suggests equity awards are an important part of retaining a very small team in a competitive biotech labor market.
Insider Trading Considerations
Insider trading patterns at a clinical-stage biotech like GRI BIO often cluster around major data readouts, financing events, and regulatory interactions rather than operating fundamentals. The company’s dependence on a small number of catalysts — especially topline clinical results for GRI-0621, FDA clearance, and future capital raises — means insiders may be highly sensitive to blackout periods and material nonpublic information. Because the firm has substantial going-concern risk and frequent equity financing needs, insider buying or selling may also reflect confidence in upcoming trial data or concerns about dilution and liquidity. Researchers and traders should watch for transaction timing around trial updates, offering announcements, and board or management changes, as those events can materially affect sentiment in a small-cap biotech with limited cash runway.
Unlock the full GRI insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.